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Introduction
Pulmonary fibrosis can be described as
an excessive amounts of fibrous
connective lung tissue in the lung.
Idiopathic pulmonary fibrosis(IPF) is the
most common form of interstitial lung
disease(ILD). When an obvious cause
cannot be determined, a diagnosis of
Idiopathic pulmonary fibrosis is made.
The mean survival for patients is
approximately 3-5 years from time of
diagnosis. IPF is found primarily in men
over 50 years of age, with a history of
cigarette smoking with concurrent
environmental and occupational
inhalation exposures(Leslie, 2011, p.
592). Pulmonary fibrosis has been
identified by early pathologists at the
beginning of the last century. During
autopsy, the signature “honeycombing”
of a shrunken, cystic and fibrotic lungs
were first identified.
IPF was first thought to an
inflammatory disorder which was
treated with corticosteroids and
cytotoxic medications. New
understanding of IPF and the
pathophysiology have shaped new
treatments. “Current concepts suggest
that the disease results from aberrant
reparative response to alveolar
epithelial cell injury characterized by
migratory proliferation, activation of
fibroblasts and secretion of excessive
amounts of extracellular matrix
components, leading to scarring of the
lungs, architectural distortion, and
irreversible loss of function”
(Tzouvelekis, Bonella & Spagnolo, 2015,
p.359). Working on a vascular thoracic
floor, many patients are admitted with a
diagnosis of IPF.

Presentation of
Case
A 76 year old man was admitted with
complaints of increased shortness of
breath and is now requiring increased
amounts of home oxygen. He is having
an elective VATS (video-assisted
thorascopic surgery) lung biopsy which
showed interstitial pneumonitis. Since
he has no acute (medicine, radiation) or
identifiable cause for pulmonary
fibrosis, he is diagnosed with idiopathic
pulmonary fibrosis. Due to his advanced
age he is not a candidate for lung
transplantation(Sheppard, 2013, p.
1055). What treatment is available for
this patient? What is his prognosis?
What will be his disease progression?

Signs and Symptoms of IPF
Signs and
Symptoms of IPF
According to the National Lung, Heart
and Blood Institute (2011), the most
common symptom of IPF is shortness of
breath. Initially a patient will have
shortness of breath with exercise, but as
the disease progresses a patient with have
shortness of breath at rest. The other late
and secondary symptoms are: increased
breathing rate, unintended weight loss,
fatigue, malaise, aching muscles and or
joints, and clubbing of the fingers. IPF
causes scarring and symptoms similar to
other common lung ailments such as COPD
(Chronic Obstructive Pulmonary Disease),
so early and correct diagnosis are very
important to patients and families.
Imaging will show traction
bronchiectasis, thickening interlobular
septae, and sub pleural honeycombing.
When all the three above are present with
no connective tissue disease or
environmental exposure, then a confident
diagnosis of IPF can be made (Noble,
Barkauskas, and Jians, 2012, p. 2756).

Misdiagnosis
Until recently, idiopathic pulmonary
fibrosis was misdiagnosed and treated
with medications which did not improve
the prognosis. Improvement of
understanding of IPF has led to the first
approved drugs to slow the progression of
the disease. Studies have been performed
looking at medication and pulmonary
rehabilitation to improve quality of life and
outcomes for pulmonary fibrosis patients.

Underlying Pathophysiology of IPF
“Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease with
few therapeutic options. Apoptosis of alveolar cells, followed by
abnormal tissue repair characterized by hyperplastic epithelial cell
formation, is a pathogenic process that contributes to the
progression of pulmonary fibrosis. However the signaling
pathways responsible for increased proliferation of epithelial cells
is poorly understood”(Weng et al. 2014, p. 1402).
IPF has been linked to:
* Cigarette smoking
* Environmental exposures
* Pharmacological Side effects
* Medical Diseases
* Virus or microbes
Understanding of role of the initial
injury and the subsequent aberrant
cellular repair has opened up new
theories and treatments for IPF.
Multiple studies have been
undertaken to find a singular
response to the initial injury, but
multiple cell and responses may be
in play with IPF(Ryu, et al, 2014, p.
1132).

Genetic
transmission
•
•
•

•
•

•

Genetics transmission may
happen in 5% of all IPF cases
Transmission is autosomal
dominant with variable and
reduced penetrance.
Genetics studies have
identified mutations only
expressed in lung epithelial
cells(Noble et al., 2012, p.
2757).
A specific gene, MUS5B has
been identified in 38% of
patients with IPF
MUS5B is only expressed in
bronchiolar, not epithelial cells
but the discovery shows
possibility of biomarkers
(Flynn, Baker, & Kass, 2015, p.
21).
Mormon death certificate
database may show larger
genetic component(Scholand,
Coon, Wolff, & CannonAlbright, 2013, p. 480)

Updated Theories
of IPF
“Several lines of evidence have
emerged implicating a combination of
environmental, age-related and genetic
factors that coalesce to create alveolar
epithelium that is susceptible to injury
from either unknown endogenous
factors or exogenous insults such as
viral infection or micro aspiration”
(Noble, et al., 2012, p. 2758).

Tyrosine Kinase is just one
isolated factor released in the
complicated pathophysiology of
IPF

•

Nurses with updated evidence
based practice information on IPF
can be an invaluable source of
education for patients and family.

•

“The factors promote
mesenchymal expansion and
activation, leading to
accumulation of matrixproducing and invasive
fibroclasts and myofibroclasts”
(Noble, et al., 2012, p. 2759).

•

New theories about IPF would
contradict recent nursing
education and treatment of
patients

•

Studies have been undertaken in
recent years show pulmonary
rehabilitation has been effective
in COPD patients, but the benefit
has been less clearly shown with
IPF measured by levels of activity
and health care quality of life
(Gaunaurd, et al., 2014, p. 1872).

•

With no curative or many
treatment options, any
rehabilitation should be studied.
2014 study of 21 IPF patients in a
randomized control trial between
groups of organized
pulmonary
.
rehab versus a control group of
no organized rehab showed
“those pulmonary rehabilitation
benefits patients with IPF by
enhancing their level of physical
activity and by significantly
reducing the disease’s symptom
burden” (Gaunaurd, et al., 2014,
p. 1878).

•

Mesenchymal expansion and
destruction leads to the
distinctive honeycombing effect
of pulmonary fibrosis and poor
oxygen/carbon dioxide exchange
in alveolar cells.

•

The damage is non-reversible and
leads to the poor prognosis
associated with IPF

•

Three studies published in 2014
showed when patients were given
either nintedanib or pierfenidone
had significant lower rate of
decline of FVC versus patients
receiving placebo at 52 weeks
(Mandel et al., 2014, p. 117).

•

The research shows the first
substantial medical treatment of
IPF

•

Results of the three studies must
be examined and looked at much
closer

Tyrosine Kinase
Role in IPF
•

Epithelium-mesenchymal cross talk
and destruction of mesenchymal
expansion shows the attempt to
repair damage by alveolar
epithelial type 2 cells (AE2C) that
release growth factors, cytokines
and coagulants. Tyrosine kinase
has been linked to IPF in recent
studies (Noble, et al., 2012, p.
2759).

•

The discovery of the role of
tyrosine kinase in IPF has led to the
development of the first FDA
approved drugs in 2014

•

Tyrosine kinase inhibitors:
Nintedanib and Pirfenidone

Nursing ImplicationsDuck, A., Spencer,References
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Significance of Patho
•

•

•

•

•

Even with exciting research
results two limitations identified
by the study authors need to be
taken into account
First, the studies did not look at
the beneficial effects past 52
weeks or the effect on mortality
and morbidity
Second, the authors caution both
drugs do not cure IPF, only
slowing the progression of the
disease
The hope would be slower
progression of the disease will
help lead to more time to find a
lung transplant donor for
patients with IPF. Lung
transplant is the only known
curative treatment today

•

Conclusion
•
•

•
•

•

IPF can be similar in symptoms and
presentation with other lung
diseases
The sooner IPF can be diagnosed
has been shown to reduce stress
reported by patients with IPF
(Duck, et al., 2014, p. 1055).
IPF is rare when compared to COPD,
care must be taken to differentiate
between the two diseases
Time is critical for IPF patients to be
evaluated for possible lung
transplantation. New drugs and
interventions need to be studied in
this population
Pathophysiological understanding
of this disease has lead to exciting
treatments and most of all some
hope for patients and families
dealing with this terrible diagnosis
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